Immunitas Therapeutics to Showcase Promising Clinical Findings of IMT-009 at AACR 2026 Annual Meeting

Immunitas Therapeutics to Present Clinical Data on IMT-009

Immunitas Therapeutics, a cutting-edge precision immunotherapy firm, is scheduled to present pivotal clinical data concerning its lead candidate IMT-009 at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026, in San Diego, California. IMT-009, an innovative anti-CD161 antibody, targets various malignancies, showcasing potential in treating both solid tumors and hematologic cancers.

Presentation Details

The clinical trial data that will be presented delineates insights from a Phase 1/2a study, which examines the utility of IMT-009 as both a standalone therapy and in combination with the treatment fruquintinib for patients suffering from microsatellite stable colorectal cancer (MSS CRC). The presentation will occur on April 20, 2026, from 9:00 AM to 12:00 PM PT in the poster section 50, featuring insights from Dr. Susanna V. Ulahannan from The University of Oklahoma.

What is IMT-009?

IMT-009 is a fully human monoclonal antibody designed to specifically engage with the CD161 pathway, a critical component that influences immune responses against tumors. By preventing CD161 from linking with its ligand, CLEC2D, IMT-009 enhances anti-tumor activity, positioning it as a promising candidate in oncology therapeutics. This antibody has successfully passed initial trials indicating its safety, tolerability, and potential effectiveness, paving the way for its further development.

The Phase 1/2a trial primarily scrutinizes the safety and efficacy of this treatment across differing cancer types, while also assessing its pharmacodynamic biomarkers. The investigation aims to establish a Recommended Phase 2 Dose (RP2D) that will guide subsequent studies.

The Vision of Immunitas Therapeutics

Founded in 2019, Immunitas Therapeutics is dedicated to pioneering antibody-based therapeutics for patients burdened by cancer and autoimmune diseases. The firm’s nuanced understanding of immunological response pathways, particularly the CD161 interaction, has allowed it to foster an innovative pipeline that includes IMT-009 and IMT-380, which targets autoimmune disorders.

The company has successfully acquired robust financial backing, amassing over $120 million from leading global investors such as Agent Capital, Evotec, and Novartis Venture Fund. This capital will further enhance their capabilities in trial execution and product development.

The upcoming AACR 2026 Annual Meeting serves as an essential platform for Immunitas to share critical data and expand on the therapeutic potential of their novel agent, bolstering their commitment to making strides in cancer treatment.

As the field of immunotherapy continues to evolve rapidly, the insights from this meeting could potentially shape future strategies for integrating innovative approaches in clinical practice, thereby extending hope to countless patients fighting cancer.

For more information about Immunitas Therapeutics and their groundbreaking work, visit www.immunitastx.com.